RegMedNet’s Post

🔬 📈 Biotech investors and corporate development professionals We've just launched Gosset, the platform that provides insights about biotech assets. Try our demo here: https://lnkd.in/gK2mUiTm and comment on this post to get early access to the full version (or just to help us spread the word:)

In this upcoming webinar, Cook MyoSite's Adam Hostetler will divulge industry secrets for fostering successful biotech partnerships, detailing the importance of defining mutual goals, data sharing guidelines and more. Register now >>> https://hubs.ly/Q02xfyS80

Register for this webinar and hear from Adam Hostetler, Director of Business operations at Cook MyoSite, about the intricate world of biotech partnerships. Hostetler reveals industry expertise for defining mutual objectives, establishing data sharing guidelines and more >>> https://hubs.ly/Q02xft__0

Thoughts on this? >> Siduma, a biotech from Arvinas' scientific founder, shutters due to 'financing environment' >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #productmarketing #healthcare #pharma #pharmaceutical

Thoughts on this? >> Siduma, a biotech from Arvinas' scientific founder, shutters due to 'financing environment' >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #biotech #pharma #productmarketing #healthcare

Register for this webinar and hear from Adam Hostetler, Director of Business operations at Cook MyoSite, about the intricate world of biotech partnerships. Hostetler reveals industry expertise for defining mutual objectives, establishing data sharing guidelines and more >>> https://hubs.ly/Q02xfDg90

Dear colleagues, dear friends, For new commercial-stage Biotech companies – with the US launch coming up or fully underway – sooner than later an urgent question occurs: “How can we maintain revenue growth once our new product reaches its sales plateau in the US market?” Over the past months, our consulting team had many discussions with new commercial-stage US Biotech companies and ran several analyses re. the commercial and financial feasibility of a European market entry: > Licensing-out for Europe is the most often favored option by new commercial-stage US Biotechs > Licensing-out for Europe is in many analysis cases NOT the best option for new commercial-stage US Biotechs > Complexity of European Market Access regulations and Willingness-to-Pay are perceived as major hurdles for pursuing the European market opportunity > Funding of a European market entry (or expansion) is regarded as a major challenge, due to the resource requirements of the initial US Launch > Finding & integrating the necessary (un-biased) expertise (Market Access, Pricing & Reimbursement, Business Model & Go-to-Market, Commercial & Financial Analysis) is difficult and challenging > Entering the European market can offer significant incremental revenue streams & company growth mid- to long-term Based on six defined Strategic Options for a potential European market entry (or expansion), we have developed “The Bridge”, a concept with a structured process and tailored proprietary analytical tools, to analyze and conclude on the optimal European Strategy: from “Out-licensing” to “Market yourself” to “Out-sourcing” to “No entry at all”. Our initial "Financial Acid Test" (FAT), a focused 3-week analysis, will provide first important insights re. the commercial feasibility of a new product for the European market – helping to decide whether or not to move forward with an in-depth analysis of the opportunities, strategies and operational requirements of a potential expansion into the European market. More information about FAT can be found at: 1d3d0b_ca2f470151f4444e8d275ec25d29c089.pdf (bridgeforgrowth.com) Please don’t hesitate to share this post with anyone who might be interested. Greetings, Tom

Thoughts on this? >> CEO Noubar Afeyan on how Flagship’s newest fund could shape biotech’s future >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #healthcare #productmarketing #pharma #pharmaceutical

Should biotech companies consider pricing implications for Early Access Programs? In this snippet from our recent webinar with Fierce Biotech, Andrew Cummins (VP of Business Development) gives his expert thoughts and advice. Download valuable insights from our latest webinar! Visit: https://lnkd.in/eP4C3bFU #ExpandedAccessPrograms #RareDiseases #OrphanDrugs #RealWorldEvidence #MarketAccess #biotechs Mathieu Loiseau Sara Radenovic

Not easy to start a new company